Nyrada Inc – Nyrada Quarterly Activities Report & Appendix 4C

Highlights:
• Lead Brain Injury Program drug candidate NYR-BI03 demonstrated strong efficacy:
– rescued average 42% of the brain injury in the penumbra region.
• Good Laboratory Practice (GLP) safety testing studies have commenced and are expected
to conclude in 1HFY2025.
• First in-human Phase I clinical trial of NYR-BI03 on track to start in 2QFY2025.
• Cash position of A$5.60 million as at 31 March 2024.
• Fully subscribed placement successfully raised A$1.76 million (before costs).